^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Miripla (miriplatin)

i
Other names: SM-11355, SM 11355, DACHPM , SMP-11355
Associations
Trials
Company:
Sumitomo Pharma
Drug class:
DNA synthesis inhibitor, DNA cross linking agent
Related drugs:
Associations
Trials
10ms
Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment. (PubMed, J Control Release)
FOLFOX regimen, composed of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (OXP), has been used as clinical standard therapeutic regimen in treatments of colorectal cancer (CRC) and esophageal squamous cell carcinoma (ESCC)...Herein, a lipid core-shell nanoparticle codelivery platform was designed for simultaneous encapsulation of variant FOLFOX composed of miriplatin (MiPt), 5-Fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP), calcium folinate (CF) and PD-L1 siRNA (siPD-L1) with high efficiencies, and their synergistic anti-tumor mechanisms were studied, respectively...CF worked as the sensitizer of FdUMP. The enhanced long-term anti-tumor effect of the prepared "all-in-one" formulation compared to free drug regimen and other controls, was verified in heterotopic CRC mice models and ESCC mice models, providing new thoughts for researchers and showing a promising prospect of translation into clinical applications.
Journal
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Miripla (miriplatin)
1year
Miriplatin-loaded liposome, as a novel mitophagy inducer, suppresses pancreatic cancer proliferation through blocking POLG and TFAM-mediated mtDNA replication. (PubMed, Acta Pharm Sin B)
Both in gemcitabine (GEM)-resistant/sensitive (GEM-R/S) pancreatic cancer cells, LMPt exhibits prominent anti-cancer activity, led by faster cellular entry-induced larger accumulation of MPt. Self-assembly offers LMPt special efficacy and mechanisms. Prominent action and characteristic mechanism make LMPt a promising cancer candidate.
Journal
|
CAV1 (Caveolin 1) • TFAM (Transcription Factor A, Mitochondrial)
|
gemcitabine • Miripla (miriplatin)
over1year
Enhanced binding of β-catenin and β-TrCP mediates LMPt's anti-CSCs activity in colorectal cancer. (PubMed, Biochem Pharmacol)
Here, we report a liposome loaded with low toxicity and high effectiveness of miriplatin, lipo-miriplatin (LMPt) with high miriplatin loading, and robust stability, exhibiting a superior inhibitory effect on CSCs and non-CSCs. LMPt predominantly inhibits the survival of oxaliplatin-resistant (OXA-resistant) cells composed of CSCs...Further studies revealed that the strengthened binding of β-catenin and β-TrCP initiates ubiquitination and degradation of β-catenin induced by LMPt. In addition,the Apctransgenicmouse model, in which colon tumors are spontaneously formed, demonstrates LMPt's potent anti-non-CSCs activity in vivo.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • POU5F1 (POU Class 5 Homeobox 1) • NANOG (Nanog Homeobox)
|
oxaliplatin • Miripla (miriplatin)
over4years
Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma. (PubMed, J Gastroenterol)
Miriplatin plus irradiation had synergistic anti-tumor activity on HCC cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may possibly be effective in treating locally advanced HCC.
Journal • PARP Biomarker
|
TP53 (Tumor protein P53)
|
TP53 expression
|
Miripla (miriplatin)